“…These techniques provide promising and multiple beneficial opportunities in neurologic and psychiatric diseases (Fregni et al, 2006a; Knöchel et al, 2012; Kuo et al, 2014; Forbes et al, 2015) and also in health (Choe et al, 2016; Ward et al, 2017). More specifically, there is increasing evidence from clinical trials that both tDCS and AE can be beneficial in stroke (Duncan et al, 2003; Fregni et al, 2005; Tang et al, 2009; Brunoni et al, 2012; Marquez et al, 2015), fibromyalgia (Castillo-Saavedra et al, 2016; Fink and Lewis, 2017), Alzheimer’s disease (Ferrucci et al, 2008; Intlekofer and Cotman, 2013; Farina et al, 2014; Hsu et al, 2015; Inagawa et al, 2018), Parkinson’s disease (Fregni et al, 2006c; Schenkman et al, 2012), major depressive disorder (Fregni et al, 2006b; Kuo et al, 2014; Schuch et al, 2016; Yokoi et al, 2018), and schizophrenia treatments (Gorczynski and Faulkner, 2010; Kuo et al, 2014; Smith et al, 2015; Yokoi et al, 2018).…”